Index

Note: Page numbers of article titles are in boldface type.

A

Acrodermatitis
  lethal, 142–143
Acupuncture
  in veterinary dermatology, 191–193
Acute febrile neutrophilic vasculitis
  of skin of young Shar-Pei dogs, 127–128
Adenitis
  sebaceous
    cyclosporine for, 164–165
Allergen-specific immunotherapy
  cyclosporine effects on, 162
Allergic dermatitis
  feline
    cyclosporine for, 163
Allergy testing
  cyclosporine effects on, 162
Aloe vera
  in veterinary dermatology, 198–199
Alopecia
  feline paraneoplastic
    cutaneous manifestations of, 139
    rabies vaccine–induced vasculitis with, 104–105
American bulldog ichthyosis, 92–93
Antidepressant(s)
  tricyclic
    in pruritus management, 182–183
Antifungal(s)
  azole
    cyclosporine and
      drug interactions, 156
Antihistamine(s)
  in pruritus management, 181–182
Antimicrobial agents
  in pruritus management, 183
Antimicrobial resistance
  in staphylococci
    in small animals, 19–40. See also Staphylococcus(i), antimicrobial resistance to
Arteritis
  proliferative
    of nasal philtrum, 128
Atopic dermatitis
  canine
cyclosporine for, 162–163
pruritus and, 178
Atopy
canine, 74–76
Autoimmune diseases
  cutaneous vasculitis related to, 127
  systemic disease–associated
    cutaneous manifestations of, 148–150
Azole antifungals
cyclosporine and
drug interactions, 156

B
Bacteria
canine skin effects of, 1–2
Bacterial culture and sensitivity
  in pyoderma diagnosis, 14–16
Bacterial infections
  cutaneous vasculitis due to, 124–125
Bacterial overgrowth
  manifestations of
    unusual, 3–7
Bacterial overgrowth syndrome, 6–7
Bite(s)
insect
  cutaneous vasculitis related to, 123
Bullous impetigo
  pyoderma and, 3

C
Calcineurin inhibitors
  for cutaneous vasculitis, 129–130
Calcinosis cutis, 137
Calendula
  in veterinary dermatology, 198
CAM. See Complementary and alternative medicine (CAM)
Canine distemper virus
  cutaneous manifestations of, 147
Canine familial dermatomyositis (FDM), 100–104
  clinical features of, 100–101
  described, 100
  diagnostic considerations in, 103–104
  differential diagnosis of, 102
  historical considerations in, 100
  management of, 104
  pathophysiology of, 102–103
Capsaicin
  in veterinary dermatology, 196
Cat(s). See also entries under Feline
cyclosporine in
side effects of, 160–161
skin fragility in, 138

Cellulitis
juvenile
pyoderma vs., 7

Chamomile
in veterinary dermatology, 197–198

Chinese herbs
in veterinary dermatology, 193–194

Cimetidine

cyclosporine and
drug interactions, 157

Clindamycin resistance
to staphylococci, 25

Coagulase-negative staphylococci (CoNS)
methicillin-resistant, 24–25

Complementary and alternative medicine (CAM)
described, 189–190
in veterinary dermatology, 189–204

acupuncture, 191–193
aloe vera, 198–199
calendula, 198
capsaicin, 196
chamomile, 197–198
Chinese herbs, 193–194
hardy kiwi, 196–197
homeopathy, 194–195
oatmeal, 198
plant extracts, 195
TCM, 190–191
tea tree oil, 197
Western herbs, 195

CoNS. See Coagulase-negative staphylococci (CoNS)

Cornification
defined, 89
disorders of. See Disorders of cornification (DOC)

Cutaneous cytology
in pyoderma diagnosis, 9–14

Cutaneous paraneoplastic markers, 138–141

Cutaneous vasculitis
autoimmune diseases and, 127
classification of, 115
clinical findings in, 115–119
described, 113–114
diagnosis of, 119–120
differential diagnosis of, 120
drugs and, 121–123
familial forms of, 127–128
food-related adverse effects and, 126–127
Cutaneous (continued)
genetics and, 127–128
histologic features of, 114–115
hypersensitivity reactions and, 114
immunopathogenesis of, 114
infectious causes of, 123–126
insect bites and, 123
neoplastic processes and, 126
in small animals, 113–134
treatment of, 128–131
avoidance of triggers in, 128–129
calcineurin inhibitors in, 129–130
cytotoxic agents in, 130
dosing alternatives in, 131
drugs targeting neutrophil function in, 130–131
glucocorticoids in, 129
pentoxiphylline in, 130
sulfasalazine and dapsone in, 131
tetracycline/niacinamide in, 130–131
xanthin derivatives in, 130
triggers of, 120–128
underlying diseases associated with, 120–128
Cutaneous xanthomas, 145
Cyclosporine
agent interactions with, 156–157
azole antifungals, 156
cimetidine, 157
grapefruit juice, 157
metoclopramide, 156
St. John’s wort, 157
allergen-specific immunotherapy effects of, 162
allergy testing effects of, 162
blood levels of
monitoring of, 155–156
described, 153
formulations of, 153–154
for immune-mediated skin diseases, 163–165
mechanism of action of, 154
patient monitoring with, 166
pharmacokinetics of, 154–155
side effects of
 canine, 157–159
feline, 160–161
vaccination effects of, 161
in veterinary dermatology, 153–171
uses/indications, 162–165
Cyst(s)
interdigital follicular, 84–86
Cytotoxic agents
for cutaneous vasculitis, 130
Dapsone  
sulfasalazine and  
for cutaneous vasculitis, 131

Demodicosis  
canine, 58–63

Dermatitis  
allergic  
feline  
cyclosporine for, 163
atopic  
canine  
cyclosporine for, 162–163  
pruritus and, 178
exfoliative  
feline thymoma–associated, 139
superficial necrolytic, 143–145  
canine, 78–79

Dermatofibrosis  
nodular, 139–140

Dermatopathy(ies)  
ischemic, 99–111. See also Ischemic dermatopathies

Dermatophytosis  
canine, 63–67

Dermatosis  
generic dog food, 142  
vitamin A–responsive  
canine, 94–95  
zinc responsive, 141–142

Dips  
for drug-resistant pyoderma in small animals, 44

Disorders of cornification (DOC)  
canine, 89–97  
diagnosis of, 90  
generalized sebaceous gland hyperplasia of terriers, 95  
pathophysiology of, 90–91  
primary  
treatment of, 94  
unconfirmed, 94–95  
primary seborrhea  
controversial issues related to, 95–96

Distemper virus  
canine  
cutaneous manifestations of, 147

DOC. See Disorders of cornification (DOC)

Dog(s). See also entries under Canine  
cyclosporine in  
side effects of, 157–159  
pododermatitis in, 57–87. See also Pododermatitis, canine  
skin of
Dog(s) (continued)
   bacteria effects on, 1–2
Drug-resistant pyoderma
   topical therapy for
      in small animals, 41–50. See also Pyoderma, drug-resistant, topical therapy for

E
Eosinophilic granuloma complex
   feline
      cyclosporine for, 163
Epidermal barrier dysfunction
   pruritus related to, 179–180
Epitheliotropic lymphoma
   canine, 81–83
Erythema multiforme
   cutaneous manifestations of, 148–149
Exfoliative dermatitis
   feline thymoma–associated, 139
Exfoliative superficial pyodermas, 3–4

F
Familial cutaneous vasculopathy of German shepherd, 107–108
Familial dermatomyositis (FDM)
   canine, 100–104. See also Canine familial dermatomyositis (FDM)
Familial paw pad hyperkeratosis
   canine, 83–84
Familial pyogranuloma
   vasculitis of Scottish terriers and, 127
Fatty acids
   in pruritus management, 183
FDM. See Familial dermatomyositis (FDM)
Feline herpes virus
   cutaneous manifestations of, 147–148
Feline otitis, 51–56
   described, 51–52
   diagnosis of, 54
   differential diagnosis of, 52–54
   treatment of, 54–56
Feline paraneoplastic alopecia
   cutaneous manifestations of, 139
Feline retroviruses
   cutaneous manifestations of, 147
Feline thymoma–associated exfoliative dermatitis, 139
Fistula(s)
   perianal
      cyclosporine for, 164
Fluoroquinolone resistance
   to staphylococci, 26
Food(s)
   adverse reactions to
cutaneous vasculitis related to, 126–127

Foreign body conditions
  canine paw effects of, 84–86

Furunculosis
  canine, 67–69
  post-grooming, 5–6

G

Generalized sebaceous gland hyperplasia of terriers, 95
Generic dog food dermatosis, 142
Genetic(s)
  cutaneous vasculitis related to, 127–128
Genetic diseases
  of paws
    canine, 83–84
German shepherd
  familial cutaneous vasculopathy of, 107–108
Glucocorticoid(s)
  for cutaneous vasculitis, 129
Golden retriever ichthyosis, 92
Grapefruit juice
  cyclosporine and
    interactions of, 157

H

Hardy kiwi
  in veterinary dermatology, 196–197
Hepatocutaneous syndrome
  canine, 78–79
Herb(s)
  Chinese
    in veterinary dermatology, 193–194
  Western
    in veterinary dermatology, 195
Herpes virus
  feline
    cutaneous manifestations of, 147–148
    cyclosporine and, 161
Homeopathy
  in veterinary dermatology, 194–195
Hormonal disturbances
  cutaneous changes associated with, 136–138
Hyperadrenocorticism
  cutaneous changes associated with, 136–137
Hyperestrogenism
  cutaneous manifestations of, 138
Hyperkeratosis
  familial paw pad
    canine, 83–84
Hypothyroidism
  cutaneous changes associated with, 136
Ichthyosis

Canine, 89–97
- American bulldog, 92–93
- Differential diagnosis of, 93–94
- Epidermolytic, 91
- General, 91
- Golden retriever, 92
- Jack Russell terrier, 93
- Noncharacterized, 93
- Nonepidermolytic, 91

Idiopathic ischemic dermatopathy, 107

Immune-mediated skin diseases
- Cyclosporine for, 163–165

Immunologic diseases of paws
- Canine, 71–78. See also Pododermatitis, canine

Immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis pyoderma vs., 8

Immunotherapy
- Allergen-specific
- Cyclosporine effects on, 162

Infectious diseases of canine paws, 58–71. See also specific diseases and Pododermatitis, canine

Inherited diseases of paws
- Canine, 83–84

Insect bites
- Cutaneous vasculitis related to, 123

Interdigital follicular cysts
- Canine, 84–86

Internal diseases
- Cutaneous manifestations of, 135–152
- Autoimmune skin diseases associated with systemic disease, 148–150
- Cutaneous paraneoplastic markers, 138–141
- Cutaneous xanthomas, 145
- Described, 135–136
- Feline paraneoplastic alopecia, 139
- Feline thymoma–associated exfoliative dermatitis, 139
- Generic dog food dermatosis, 142
- Hormonal disturbances and, 136–138
- Leishmaniasis, 146
- Lethal acrodermatitis, 142–143
- Nodular dermatofibrosis, 139–140
- Nutritional and metabolic perturbations, 141–145
- PNP, 140–141
- SND, 143–145
- Systemic infectious diseases, 146–148
- Systemic mycosis, 146–147
- Testicular tumors, 138
**Ischemic dermatopathies**, 99–111. See also specific disorders
canine FDM, 100–104
described, 99–100
familial cutaneous vasculopathy of German shepherd, 107–108
idiopathic, 107
proliferative thrombovascular necrosis of pinnae, 108
rabies vaccine–induced vasculitis with alopecia, 104–105
treatment of
  pharmacologic, 108
vaccine-associated, 105–107
Ischemic vasculopathies
treatment of
  pharmacologic, 108
Itch. See also Pruritus
defined, 173

**J**
Jack Russell terrier ichthyosis, 93
Juvenile cellulitis
  pyoderma vs., 7

**L**
Leishmaniasis
cutaneous manifestations of, 146
Lethal acrodermatitis, 142–143
Lymphoma(s)
  epitheliotropic
canine, 81–83

**M**
Malassezia
canine, 69–71
Metabolic diseases
  of paws
canine, 78–79
Metabolic epidermal necrosis
canine, 78–79
Methicillin resistance
  in staphylococci
  in small animals, 20–25. See also Staphylococcus(i), methicillin-resistant
Methicillin-resistant CoNS, 24–25
Methicillin-resistant *Staphylococcus aureus* (MRSA), 22–23
Methicillin-resistant *Staphylococcus pseudintermedius* (MRSP), 20–22
Methicillin-resistant *Staphylococcus schleiferi* (MRSS), 23–24
Metoclopramide
cyclosporine and
drug interactions, 156
MRSA. See Methicillin-resistant Staphylococcus aureus (MRSA)
MRSP. See Methicillin-resistant S. pseudintermedius (MRSP)
MRSS. See Methicillin-resistant Staphylococcus schleiferi (MRSS)
Mucocutaneous pyoderma, 4–5
Mycosis
  systemic
cutaneous manifestations of, 146–147

N
Nail bed squamous cell carcinoma
canine, 79–81
Nasal philtrum
  proliferative arteritis of, 128
Necrolytic migratory erythema
canine, 78–79
Neoplastic diseases
  of paws
canine, 79–83
Neoplastic processes
  cutaneous vasculitis related to, 126
Nodular dermatofibrosis, 139–140

O
Oatmeal
  in veterinary dermatology, 198
Ointment/cream/gel/liquid therapy
  for drug-resistant pyoderma in small animals, 43–44
Otitis
  feline, 51–56. See also Feline otitis

P
Paraneoplastic markers
  cutaneous, 138–141
Paraneoplastic pemphigus (PNP)
  cutaneous manifestations of, 140–141
Parasitic diseases
  of canine paws, 58–71. See also specific diseases and Pododermatitis, canine
Paw(s)
  infectious/parasitic diseases of
canine, 58–71. See also specific diseases and Pododermatitis, canine
Pemphigus foliaceus
canine, 71–74
cyclosporine for, 165
pyoderma vs., 8
Pentoxiphylline
  for cutaneous vasculitis, 130
Perianal fistula
cyclosporine for, 164
Pinnal margin vasculopathy, 108
Plant extracts
in veterinary dermatology, 195
PNP. See Paraneoplastic pemphigus (PNP)
Pododermatitis
 canine, 57–87
described, 57–58
foreign body conditions and, 84–86
immunologic diseases, 71–78
 atopy, 74–76
 pemphigus foliaceus, 71–74
 vasculitis, 76–78
infectious/parasitic diseases, 58–71
deep pyoderma/furunculosis, 67–69
demodicosis, 58–63
dermatophytosis, 63–67
malassezia, 69–71
inherited/genetic diseases, 83–84
metabolic diseases, 78–79
neoplastic diseases, 79–83
epitheliotropic lymphoma, 81–83
nail bed squamous cell carcinoma, 79–81
Post-grooming furunculosis, 5–6
Primary seborrhea
canine
controversial issues related to, 95–96
Proliferative thrombovascular necrosis of pinnae, 108
Pruritus
 atopic dermatitis and, 178
causes of, 174
defined, 173
epidermal barrier dysfunction and, 179–180
pathogenesis of, 179
treatment of, 173–187
 antihistamines in, 181–182
 antimicrobial agents in, 183
 bathing in, 178
 components of good skin care in, 178–179
 fatty acids in, 183
 lipid replacement lotions in, 180–181
 nonsteroidal, nonimmunosuppressive therapies in, 173–187
 overview of, 174
 systemic, 181–183
 TCAs in, 182–183
topical
 mechanism of action of, 175–177
 overview of, 174–175
Puppy strangles
 pyoderma vs., 7
Pyoderma, 1–18
- conditions mistaken for, 7–9
- deep
  - canine, 67–69
- described, 2
- diagnostic testing in, 9–16
  - bacterial culture and sensitivity in, 14–16
  - cutaneous cytology in, 9–14
  - histopathology in, 16
- drug-resistant
  - topical therapy for
    - in small animals, 41–50
      - described, 41–42
      - ointment/cream/gel/liquid therapy, 43–44
      - potentiating ingredients, 45–48
      - shampoo/leave-on conditioner therapy, 42–43
      - sprays and dips, 44
      - wipes, 44–45
- exfoliative superficial, 3–4
- manifestations of
  - unusual, 3–7
  - mucocutaneous, 4–5
- treatment of
  - response to, 16

Pyogranuloma
- familial
  - vasculitis of Scottish terriers and, 127

R

Rabies vaccine–induced vasculitis with alopecia, 104–105

Retrovirus(es)
- feline
  - cutaneous manifestations of, 147

S

Scottish terriers
- vasculitis of
  - familial pyogranuloma and, 127

Sebaceous adenitis
- cyclosporine for, 164–165

Seborrhea
- primary
  - canine
    - controversial issues related to, 95–96

Shampoo/leave-on conditioner therapy
- for drug-resistant pyoderma in small animals, 42–43

Shar-Pei dogs
- acute febrile neutrophilic vasculitis of skin of, 127–128

Skin care
- good
components of, 178–179

Skin diseases

  immune-mediated
cyclosporine for, 163–165

Skin fragility

  feline-acquired, 138

SND. See Superficial necrolytic dermatitis (SND)

Sprays

  for drug-resistant pyoderma in small animals, 44

Squamous cell carcinoma

  nail bed
canine, 79–81

St. John’s wort

cyclosporine and
interactions of, 157

Staphylococcus(i)

  antimicrobial resistance to, 19–40

    clindamycin resistance, 25

    culture and susceptibility testing related to
    indications for, 26–27

    described, 19

    fluoroquinolone resistance, 26

    implications of, 26–29

    infection prevention and decolonization, 29

    mechanisms of, 20–26

    methicillin resistance, 20–25

    rational empiric therapy for, 27

    tetracycline resistance, 26

  coagulase-negative

    methicillin-resistant, 24–25

  methicillin-resistant, 20–25

    MRSA, 22–23

    MRSP, 20–22

    MRSS, 23–24

  treatment of, 27–29

Staphylococcus spp.

  S. aureus

    methicillin-resistant, 22–23

  S. pseudintermedius

    methicillin-resistant, 20–22

  S. schleiferi

    methicillin-resistant, 23–24

Sterile nodular panniculitis

  cutaneous manifestations of, 149–150

Stratum corneum

  function of, 89–90

Sulfasalazine

dapsone and

  for cutaneous vasculitis, 131

Superficial necrolytic dermatitis (SND), 143–145

  canine, 78–79
Systemic diseases
  autoimmune skin disorders associated with cutaneous manifestations of, 148–150
  infectious cutaneous manifestations of, 146–148
Systemic lupus erythematosus (SLE)
  cutaneous manifestations of, 148
Systemic mycosis
  cutaneous manifestations of, 146–147

T
TCAs. See Tricyclic antidepressants (TCAs)
TCM. See Traditional Chinese medicine (TCM)
Tea tree oil
  in veterinary dermatology, 197
Terriers
  generalized sebaceous gland hyperplasia of, 95
Testicular tumors
  cutaneous manifestations of, 138
Tetracycline/niacinamide
  for cutaneous vasculitis, 130–131
Tetracycline resistance
  to staphylococci, 26
Tick(s)
  cutaneous vasculitis related to, 125–126
Toxoplasmosis
  cyclosporine in cats and, 160–161
Traditional Chinese medicine (TCM)
  in veterinary dermatology, 190–191
Tricyclic antidepressants (TCAs)
  in pruritus management, 182–183
Tumor(s)
  testicular
    cutaneous manifestations of, 138

V
Vaccination(s)
  cyclosporine effects on, 161
Vaccine-associated ischemic dermatopathy, 105–107
Vasculitis
  acute febrile neutrophilic
    of skin of young Shar-Pei dogs, 127–128
    canine, 76–78
  cutaneous, 113–134. See also Cutaneous vasculitis
    defined, 113
    rabies vaccine–induced
      with alopecia, 104–105
    of Scottish terriers
      familial pyogranuloma and, 127
Vasculopathy(ies)
  ischemic
treatment of  
  pharmacologic, 108  
  pinnal margin, 108  
Viral diseases  
  cutaneous manifestations of, 147–148  
Viral infections  
  cutaneous vasculitis due to, 124  
Vitamin A–responsive dermatosis  
  canine, 94–95  

W  
Western herbs  
  in veterinary dermatology, 195  
Wipes  
  for drug-resistant pyoderma in small animals, 44–45  

X  
Xanthin derivatives  
  for cutaneous vasculitis, 130  
Xanthoma(s)  
  cutaneous, 145  

Z  
Zinc responsive dermatosis, 141–142